Exploring The Potential of C4A as A Drug Target Or Biomarker (G720)

Target Name: C4A

NCBI ID: G720

Content of Review Report on C4A Target / Biomarker

C4A

Exploring The Potential of C4A as A Drug Target Or Biomarker

C4A (C4A6) is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, kidneys, and gastrointestinal tract. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling.

C4A is unique among its family members because of its unique expression pattern in different tissues. While other GPCR proteins are widely expressed across various tissues, C4A is primarily expressed in the brain and testes, making it a promising drug target or biomarker in these fields.

One of the key reasons for the potential of C4A as a drug target is its involvement in several important signaling pathways. For example, C4A is involved in the regulation of neurotransmitter release, which is critical for proper brain function. Additionally, C4A is involved in the regulation of pain perception and neuroinflammation, which are important for maintaining brain health and function.

Another promising aspect of C4A is its potential as a biomarker for certain neurological disorders. For example, C4A is expressed in the brains of individuals with Alzheimer's disease, which is a leading cause of dementia and Alzheimer's disease. Therefore, levels of C4A may be a useful biomarker for the diagnosis and progression of this disease.

In addition to its potential as a drug target and biomarker, C4A is also of interest to researchers because of its unique structure and biology. Unlike many other GPCR proteins, C4A has a unique farnesylated cysteine residue, which is important for its stability and function. Additionally, C4A has a unique transmembrane domain, which is involved in its localization and interactions with other proteins.

Overall, C4A is a promising protein that has the potential to be a drug target or biomarker. Its unique expression pattern and biology make it an attractive target for research, and its involvement in several important signaling pathways makes it a valuable addition to the growing list of potential drug targets. Further research is needed to fully understand the role of C4A in neural function and disease.

Protein Name: Complement C4A (Rodgers Blood Group)

Functions: Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens

The "C4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets